Kim Domela Kjoeller

moksha8 Pharmaceuticals, Inc. operates as a pharmaceutical company. It's products include viibryd, razapina, queopine, benexafrina, arasid, ziledon, zopina, and rispalum. The firm offers a portfolio of therapeutics for bipolar disorders and schizophrenia. The company was founded by Balkrishan Gill in 2007 and is headquartered in Berwyn, PA.

Modul 1 Data AB offers consulting and professional services. The firm provides knowledge-specific IT solutions and industry-specific business and eServices. Its IT consulting group develops, provides quality assurance and maintenance of business supporting IT solutions. The company was founded in 1991 and is headquartered in Stockholm, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Tytex A/S provides medical textile products. Its products include continence care post surgery, ostomy and hernia, wound dressing and IV fixation, hip protection and pregnancy & nursing. The company was founded in 1971 and is headquartered in Ikast, Denmark.

GN Hearing A/S develops and sells hearings aids and tools for measuring loss of hearing capability. It provides solutions for all types of ear-related diagnostics and distributes computerized audiology and hearing-instrument fitting equipment. The company was founded in 1957 and is headquartered in Ballerup, Denmark.

ATRIUM Partners AS is engaged in the provision of financial management and advisory services. It operates through the following divisions: Corporate Finance, Debt Advisory Services, and Wealth Management. The Corporate Finance division offers strategic consulting and tactical solutions focusing on corporate negotiations such as mergers and acquisitions, initial public offering, joint ventures, privatization, divestments, private placement, and capital structure. The Debt Advisory Services division specializes in acquisition finance, restructuring, strategic debt financing, risk assessment, and cash flow analysis and cash management. The Wealth Management division offers investment, asset, and portfolio management services. The firm's clients encompass business investors, fund managers, insurance agencies, electric companies, and organizations. The company was founded in 2003 and is headquartered in Hellerup, Denmark.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

LEO Fondet provides support for research in the fields of medicine, chemistry, and pharmacy. The company was founded on August 20, 1984 and is headquartered in Ballerup, Denmark.

Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom.

Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ.

SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

Lundbeck Pharma A/S markets and sells medicines within Central Nervous System. It specializes in various illnesses and conditions such as depression, Schizophrenia, anxiety, alcohol dependence, and Parkinson's and Alzheimer's diseases. The company was founded on January 1, 1988 and is headquartered in Valby, Denmark.

H. Lundbeck AS trades pharmaceutical and healthcare products. It provides drugs for the treatment of depression, schizophrenia, alzheimers, and Parkinsons diseases. The company was founded in 1948 and is headquartered in Lysaker, Norway.

Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital.

Catacap Management ApS (CataCap) is an independent Danish private equity firm which was founded in 2011 by Vilhelm Hahn-Petersen, Jens Hahn-Petersen And Peter Ryttergaard. Headquartered in Niva, the firm invests in Danish SMEs characterized by significant development potential and an innovative, long-term, sustainable business model. They aim to act as a catalyst for sustainable step changes through a consistent, systematic approach to business development. CataCap manages the Catcap funds, backed by Dansk Vækstkapital, Danica Pension, Lægernes Pensionskasse, the firm's partners and private investors. To align the interests of investors and the firm, the partners and operating partners invest alongside their fund. CataCap operates in accordance with international guidelines for Corporate Social Responsibility and has adopted the UN Global Compact as the framework by which they and their investee companies ensure continuous CSR development.

Broen-Lab A/S manufactures laboratory fittings and emergency shower systems used in professional laboratories, education sector and industrial workplaces. Its product portfolio includes valves and fittings for the control and regulation of a wide range of medias and the emergency shower product portfolio (ESS) includes a wide range of eye and body showers. The company was founded by Poul Boren in 1948 and is headquartered in Assens, Denamark.

Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark.

AntibioTx ApS develops and manufactures pharmaceutical products. The private company is based in Kongens Lyngby, Denmark.

LEO Holding A/S invests in company with interest in medical dermatology. The company was founded on November 29, 2017 and is headquartered in Copenhagen, Denmark.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.

StemMedical A/S provides a cell-enriched fat grafting solution for cosmetic treatments. The company is based in Soborg, Denmark. The Danish company was founded in 2014 by Stig-Frederik Trojahn Kølle.

Transmedica A/S provides patients with specialized treatment. It operates as health care provider, which recruits and sends health workers and agency staff to public and private hospitals in the Scandinavian healthcare sector. The firm's activities are divided into main business units temporary help; private hospitals and clinics; and other health services. It also runs clinics specialized in weight loss surgery, eye surgery, orthopedics, rheumatology, and psychiatry. The company was founded by Karsten Ramløv Svendsen in 1990 and is headquartered in Copenhagen, Denmark.